Understanding DTD2: A Potential Drug Target and Biomarker (G112487)

Target Name: DTD2

NCBI ID: G112487

Understanding DTD2: A Potential Drug Target and Biomarker

DTD2 (double transmembrane domain) is a protein that is expressed in various tissues and cell types in the human body. It is involved in several cellular processes, including cell signaling, migration, and invasion. DTD2 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DTD2 has emerged as a promising drug target and biomarker.

DTD2 is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, heart, and skin. It is involved in several cellular processes, including cell signaling, migration, and invasion. DTD2 has been shown to play a role in several cellular processes that are important for human health, including:

1. Cell signaling: DTD2 has been shown to be involved in several signaling pathways that are important for human health. For example, DTD2 has been shown to be involved in the development and progression of cancer, including breast cancer. It has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
2. Migration: DTD2 has been shown to be involved in the migration of cells. This is important for the development of cancer, as cancer cells are able to migrate to new locations in the body and can invade other tissues.
3. Invasion: DTD2 has also been shown to be involved in the invasion of cells. This is important for the development of cancer, as cancer cells are able to invade other tissues and can establish new colonies.

DTD2 has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, DTD2 has been shown to be involved in the development and progression of breast cancer. It has also been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Despite these promising findings, much more research is needed to fully understand the role of DTD2 in human health. As a result, DTD2 has emerged as a promising drug target and biomarker. Researchers are currently working to develop new treatments for DTD2-related diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, DTD2 is a protein that is involved in several cellular processes that are important for human health. It has also been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, DTD2 has emerged as a promising drug target and biomarker. Researchers are currently working to develop new treatments for DTD2-related diseases.

Protein Name: D-aminoacyl-tRNA Deacylase 2

Functions: Deacylates mischarged D-aminoacyl-tRNAs (By similarity). Also deacylates mischarged glycyl-tRNA(Ala), protecting cells against glycine mischarging by AlaRS (By similarity). Probably acts by rejecting L-amino acids from its binding site rather than specific recognition of D-amino acids (By similarity). Catalyzes the hydrolysis of D-tyrosyl-tRNA(Tyr), has no activity on correctly charged L-tyrosyl-tRNA(Tyr) (By similarity). By recycling D-aminoacyl-tRNA to D-amino acids and free tRNA molecules, this enzyme counteracts the toxicity associated with the formation of D-aminoacyl-tRNA entities in vivo and helps enforce protein L-homochirality. In contrast to DTD1, deacylates L-Ala mischarged on tRNA(Thr)(G4.U69) by alanine-tRNA ligase AARS (PubMed:29410408). Can deacylate L-Ala due to a relaxed specificity for substrate chirality caused by the trans conformation of the Gly-Pro motif in the active site (PubMed:29410408). Also hydrolyzes correctly charged, achiral, glycyl-tRNA(Gly) in vitro, although in vivo EEF1A1/EF-Tu may protect cognate achiral glycyl-tRNA(Gly) from DTD2-mediated deacetylation (By similarity)

More Common Targets